Syndax Pharmaceuticals (NASDAQ:SNDX) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Syndax Pharmaceuticals (NASDAQ:SNDX) announced its earnings results on Thursday. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.11, Zacks reports. Syndax Pharmaceuticals had a negative net margin of 111.88% and a negative return on equity of 216.23%. The business had revenue of $64.86 million during the quarter, compared to the consensus estimate of $69.76 million. During the same quarter in the prior year, the firm earned ($0.98) earnings per share. The business’s quarterly revenue was up 224.3% compared to the same quarter last year.

Here are the key takeaways from Syndax Pharmaceuticals’ conference call:

• Combined Q1 sales topped $100 million — Revuforj net revenue was $48.9M (double?digit QoQ growth) and NICTIMVO net revenue was $55M (Syndax recorded $15.9M collaboration revenue), with both products annualizing near $200M.
• Revuforj is driving higher transplant rates in KMT2A — recent analysis shows nearly 50% of KMT2A patients are proceeding to stem?cell transplant (up from ~33%), ~45% have restarted therapy post?transplant so far, and management expects 70–80% long?term, a dynamic the company calls a short?term revenue headwind that should lengthen treatment durations and support sustainable growth.
• Frontline revumenib program advancing — global site activation and enrollment are underway in pivotal Phase III trials (EVOLVE?2, REVEAL) and the RAVEN Phase II, and Syndax expects to be first to report pivotal frontline menin?inhibitor data with multiple presentations planned at ASCO, EHA and ASH.
• Two potentially transformative axatilimab readouts due in Q4 2026 — topline Phase II data for axatilimab plus ruxolitinib in chronic GVHD and the MAXPIRe IPF trial could materially expand market opportunity if positive, supported by a clear mechanistic rationale and encouraging GVHD lung responses to date.
• Strong cash runway and disciplined expense guidance — $352.1M in cash and marketable securities as of March 31, 2026, and guidance for ~ $400M total R&D+SG&A in 2026 (ex?$50M non?cash stock comp), which management says positions the company to continue investing and move toward profitability.

Syndax Pharmaceuticals Stock Performance

NASDAQ:SNDX traded down $2.35 during mid-day trading on Friday, reaching $19.08. The stock had a trading volume of 4,675,388 shares, compared to its average volume of 1,349,811. The company has a debt-to-equity ratio of 5.32, a quick ratio of 4.12 and a current ratio of 4.40. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of -5.80 and a beta of 0.41. Syndax Pharmaceuticals has a twelve month low of $8.58 and a twelve month high of $25.59. The business has a 50 day simple moving average of $23.03 and a 200 day simple moving average of $20.35.

Insider Transactions at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 17,159 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $21.03, for a total value of $360,853.77. Following the completion of the transaction, the chief executive officer directly owned 491,690 shares of the company’s stock, valued at approximately $10,340,240.70. This trade represents a 3.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Keith A. Goldan sold 3,410 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $21.03, for a total transaction of $71,712.30. Following the completion of the transaction, the chief financial officer directly owned 140,429 shares of the company’s stock, valued at approximately $2,953,221.87. This trade represents a 2.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 30,063 shares of company stock valued at $628,332. 4.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Larson Financial Group LLC increased its holdings in Syndax Pharmaceuticals by 192.2% in the third quarter. Larson Financial Group LLC now owns 2,922 shares of the company’s stock valued at $45,000 after buying an additional 1,922 shares in the last quarter. Quantbot Technologies LP purchased a new position in Syndax Pharmaceuticals in the third quarter valued at about $53,000. Smartleaf Asset Management LLC increased its holdings in Syndax Pharmaceuticals by 2,698.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,659 shares of the company’s stock valued at $55,000 after buying an additional 2,564 shares in the last quarter. Lazard Asset Management LLC purchased a new position in Syndax Pharmaceuticals in the second quarter valued at about $66,000. Finally, Tower Research Capital LLC TRC increased its holdings in Syndax Pharmaceuticals by 103.3% in the second quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company’s stock valued at $79,000 after buying an additional 4,308 shares in the last quarter.

Syndax Pharmaceuticals News Roundup

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Barclays raised its price target to $37 and upgraded SNDX to “overweight,” implying large upside versus the current price — a bullish analyst endorsement that can support the stock. Barclays Raises Price Target
• Positive Sentiment: Commercial traction: management reported strong product sales (Revuforj/revumenib net revenue ~$48.9M) and collaboration revenue tied to Niktimvo, driving total revenue up ~224% YoY — and the company highlighted upcoming real?world/frontline data in 2Q26 and Phase 2 topline readouts in 4Q26 (near-term catalysts). Syndax Q1 Results & Business Update
• Positive Sentiment: Earnings per share beat: reported loss of $0.48 vs. consensus loss of $0.59 — an improvement from last year and a metric that can temper downside from the revenue miss. Q1 EPS Beat Summary
• Neutral Sentiment: Earnings call transcript and slide deck are available for investors who want management color on commercial uptake and pipeline timelines. Earnings Call Transcript
• Neutral Sentiment: Quick analyst/press snapshots are circulating summarizing Q1 results and the conference call; useful for catching detail but less likely to move the stock alone. Q1 Earnings Snapshot
• Negative Sentiment: Revenue missed consensus ($64.9M reported vs. ~$69.8M expected), and the company still shows negative net margin/ROE and elevated leverage metrics noted in public filings — these mixed fundamentals likely pressured the stock despite the EPS beat and analyst upgrade. Revenue Miss & Financial Metrics

Analysts Set New Price Targets

Several brokerages have recently weighed in on SNDX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a research note on Friday, March 27th. Mizuho reduced their price objective on shares of Syndax Pharmaceuticals from $45.00 to $43.00 and set an “outperform” rating for the company in a research report on Tuesday, March 31st. The Goldman Sachs Group raised their price objective on shares of Syndax Pharmaceuticals from $28.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, April 1st. Citigroup raised their price objective on shares of Syndax Pharmaceuticals from $51.00 to $57.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Finally, Barclays raised their price objective on shares of Syndax Pharmaceuticals from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $40.50.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.